These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12075505)

  • 1. [Is the life-long administration of marcumar to a young woman with recurring thromboembolic events necessary?].
    Dtsch Med Wochenschr; 2002 Jun; 127(25-26):1402. PubMed ID: 12075505
    [No Abstract]   [Full Text] [Related]  

  • 2. [The first oral thrombin inhibitor. Competition to heparins and marcumar?].
    MMW Fortschr Med; 2003 Mar; 145(10):56. PubMed ID: 12688030
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Marcumarized patient must have surgery. Playing it safe with low molecular weight heparin bridging].
    MMW Fortschr Med; 2005 Jun; 147(22):51. PubMed ID: 15977637
    [No Abstract]   [Full Text] [Related]  

  • 5. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of gonadotropin releasing hormone analogs in Marcumar-treated patients for contraception and prevention of life-threatening ovulation hemorrhages].
    Prömpeler H; Wieacker P; Hillemanns HG; Breckwoldt M
    Geburtshilfe Frauenheilkd; 1988 Aug; 48(8):588-9. PubMed ID: 3145898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once atrial fibrillation, always oral anticoagulation?
    Verheugt FW
    Thromb Res; 2007; 119(3):275-6. PubMed ID: 16426666
    [No Abstract]   [Full Text] [Related]  

  • 8. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is anticoagulation with heparins in phenprocoumon treated patients safe during operations?].
    Hoppe UC
    Dtsch Med Wochenschr; 2002 Nov; 127(44):2345. PubMed ID: 12410442
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anticoagulation in pregnancy].
    Wagner T
    Internist (Berl); 1998 Oct; 39(10):1076-7. PubMed ID: 9827382
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Schmidt-Lucke C; Paar WD; Stellbrink C; Nixdorff U; Hofmann T; Meurer J; Grewe R; Daniel WG; Hanrath P; Mügge A; Klein HU; Schmidt-Lucke JA
    Thromb Res; 2007; 119(1):27-34. PubMed ID: 16443257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticoagulation for difficult cases].
    Fischer A
    MMW Fortschr Med; 2009 Jun; 151(24):18-9. PubMed ID: 19645194
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Seneviratne C; Kupfer Y; Tessler S
    N Engl J Med; 2003 Jul; 349(4):398-400; author reply 398-400. PubMed ID: 12879892
    [No Abstract]   [Full Text] [Related]  

  • 14. Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis.
    Prandoni P; Hutten BA; van Dongen CJ; Pesavento R; Prins MH
    J Thromb Haemost; 2007 Jul; 5(7):1555. PubMed ID: 17439633
    [No Abstract]   [Full Text] [Related]  

  • 15. [The optimum length of anticoagulation therapy after venous thromboembolism--universal or individualised approach?].
    Hirmerová J
    Vnitr Lek; 2007 Jun; 53(6):662-8. PubMed ID: 17702126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of general thromboembolism prophylaxis with marcumar after major gynecological operations].
    SOERGEL W
    Zentralbl Gynakol; 1960 Jan; 82():28-35. PubMed ID: 13832444
    [No Abstract]   [Full Text] [Related]  

  • 17. [Heparin as a substitute for acetylsalicylic acid in polypectomy?].
    Vogt W
    Dtsch Med Wochenschr; 2005 Feb; 130(7):353. PubMed ID: 15712026
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor.
    Kearon C; Ginsberg JS; Anderson DR; Kovacs MJ; Wells P; Julian JA; Mackinnon B; Demers C; Douketis J; Turpie AG; Van Nguyen P; Green D; Kassis J; Kahn SR; Solymoss S; Desjardins L; Geerts W; Johnston M; Weitz JI; Hirsh J; Gent M;
    J Thromb Haemost; 2004 May; 2(5):743-9. PubMed ID: 15099280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How should anticoagulants be used in recurrent, ischemic and hemorrhagic brain infarctions?].
    Leschke M; Klimek W
    Dtsch Med Wochenschr; 2003 Oct; 128(42):2213-4. PubMed ID: 14562222
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding low INR in clinical practice.
    Hylek EM; Rose AJ
    Thromb Haemost; 2009 Mar; 101(3):417-8. PubMed ID: 19277399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.